Nephroprotection : General principles and application to the patients with cancers - when nephroprotection is essential for oncological care plan
Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved..
Nephroprotection is a set of recommendations that aim to prevent the risks of acute and/or chronic renal failure and to limit the progression of renal failure towards an end stage. Nephroprotection is not limited to nephrology and applies to all patients at risk of renal failure. Cancer patients are particularly at risk of developing intrinsic and extrinsic renal failure, as well as the toxicity of specific treatments. However, they are poorly included in nephroprotection studies. Thus, current guidelines have not been adapted to these pathologies and oncology-specific comorbidities, such as malnutrition or prognosis, are often not taken into account. In this article, we review the established recommendations by transposing them to the cancer patient as a whole. In addition to the reminder of hygiene and dietary rules to control blood pressure and diabetes, we discuss the importance of therapeutic education, iatrogeny and treatment options to control renal failure in this context. The lack of clearly established data in cancer confirms the needs to strengthen links between oncologists, hematologists and nephrologists and reinforces the emergence of onco-nephrology as a new discipline.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Bulletin du cancer - (2023) vom: 10. Okt. |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Néphroprotection : principes généraux et application au patient de cancérologie – quand la protection du rein est indispensable à la bonne conduite du plan de soin oncologique |
|---|
| Beteiligte Personen: |
Bainaud, Matthieu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Revised 12.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.bulcan.2023.05.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363209743 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363209743 | ||
| 003 | DE-627 | ||
| 005 | 20231226092846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2023.05.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM363209743 | ||
| 035 | |a (NLM)37827963 | ||
| 035 | |a (PII)S0007-4551(23)00295-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Bainaud, Matthieu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nephroprotection |b General principles and application to the patients with cancers - when nephroprotection is essential for oncological care plan |
| 246 | 3 | 3 | |a Néphroprotection : principes généraux et application au patient de cancérologie – quand la protection du rein est indispensable à la bonne conduite du plan de soin oncologique |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Nephroprotection is a set of recommendations that aim to prevent the risks of acute and/or chronic renal failure and to limit the progression of renal failure towards an end stage. Nephroprotection is not limited to nephrology and applies to all patients at risk of renal failure. Cancer patients are particularly at risk of developing intrinsic and extrinsic renal failure, as well as the toxicity of specific treatments. However, they are poorly included in nephroprotection studies. Thus, current guidelines have not been adapted to these pathologies and oncology-specific comorbidities, such as malnutrition or prognosis, are often not taken into account. In this article, we review the established recommendations by transposing them to the cancer patient as a whole. In addition to the reminder of hygiene and dietary rules to control blood pressure and diabetes, we discuss the importance of therapeutic education, iatrogeny and treatment options to control renal failure in this context. The lack of clearly established data in cancer confirms the needs to strengthen links between oncologists, hematologists and nephrologists and reinforces the emergence of onco-nephrology as a new discipline | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Insuffisance rénale chronique | |
| 650 | 4 | |a Nephroprotection | |
| 650 | 4 | |a Néphroprotection | |
| 650 | 4 | |a Proteinuria | |
| 650 | 4 | |a Protéinurie | |
| 650 | 4 | |a Renal toxicity | |
| 650 | 4 | |a Toxicité rénale | |
| 700 | 1 | |a Try, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidan, Mohamad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g (2023) vom: 10. Okt. |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:10 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2023.05.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 10 |c 10 | ||